Log in with your email address username.


[Comment] Treatment of chronic immune thrombocytopenia in children with romiplostim

In The Lancet, Michael Tarantino and colleagues1 report the outcome of a phase 3, randomised, double-blind, placebo-controlled trial of romiplostim in children with immune thrombocytopenia.1 This is the largest study of romiplostim in children and shows both its safety and efficacy.